Renal, central nervous system and pancreatic overexpression of recombinant soluble Crry in transgenic mice. A novel means of protection from complement-mediated injury

Immunopharmacology

Volumn 42, Issue 1-3, 1999, Pages 245-254

  Alexander, Jessy J ^a   Lim, Alice ^a   He, Chun ^a   MacDonald, R Loch ^a   Holers, V Michael ^b   Quigg, Richard J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Anti glomerular basement membrane disease; Central nervous system; Complement inactivators; Crry; Pancreas; Transgenic mice

Indexed keywords

ALBUMIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT; COMPLEMENT COMPONENT C3; MESSENGER RNA; METALLOTHIONEIN; RECOMBINANT PROTEIN; REGULATOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CENTRAL NERVOUS SYSTEM; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; IMMUNE COMPLEX NEPHRITIS; IMMUNOFLUORESCENCE MICROSCOPY; MALE; MOUSE; NONHUMAN; PANCREAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEINURIA; TRANSGENE;

EID: 0032992087     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(99)00010-7     Document Type: Conference Paper

References (49)

1. Bottazzo G.F., Dean B.M., Gorsuch A.N., Cudworth A.G., Doniach D. Complement-fixing islet-cell antibodies in type-I diabetes: possible monitors of active beta-cell damage. Lancet. 1:1980;668-672.
2. Bottger E.C., Hoffmann T., Hadding U., Bitter-Suermann D. Guinea pigs with inherited deficiencies of complement components C2 or C4 have characteristics of immune complex disease. J. Clin. Invest. 78:1986;689-695.
3. Boyce N.W., Holdsworth S.R. Anti-glomerular basement membrane antibody-induced experimental glomerulonephritis: Evidence for dose-dependent direct antibody and complement-induced, cell-independent injury. J. Immunol. 135:1985;3918-3921.
4. Brandt J., Pippin J., Schulze M., Hänsch G.M., Alpers C.E., Johnson R.J., Gordon K., Couser W.G. Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int. 49:1996;335-343.
5. Cochrane C.G., Müller-Eberhard H.J., Aikin B.S. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J. Immunol. 105:1970;55-69.
6. Cork L.C., Morris J.M., Olson J.L., Krakowka S., Swift A.J., Winkelstein J.A. Membranoproliferative glomerulonephritis in dogs with a genetically determined deficiency of the third component of complement. Clin. Immunol. Immunopathol. 60:1991;455-470.
7. Couser W.G. Pathogenesis of glomerular damage in glomerulonephritis. Nephrol. Dial. Transplant. 13:1998;10-15. Suppl 1.
8. Davies K.A., Schifferli J.A., Walport M.J. Complement deficiency and immune complex disease. Springer Sem Immunopathol. 15:1994;397-416.
9. Eisenbarth G.S., Morris M.A., Scearce R.M. Cytotoxic antibodies to cloned rat islet cells in serum of patients with diabetes mellitus. J. Clin. Invest. 67:1981;403-408.
10. Falk R.J., Jennette J.C. Immune complex induced glomerular lesions in C5 sufficient and deficient mice. Kidney Int. 30:1986;678-686.
11. Ferreira A., Takahashi M., Nussenzweig V. Purification and characterization of mouse serum protein with specific binding affinity for C4 (Ss protein). J. Exp. Med. 146:1977;1001-1008.
12. Foley S., Li B., Dehoff M., Molina H., Holers V.M. Mouse Crry/p65 is a regulator of the alternative pathway of complement activation. Eur. J. Immunol. 23:1993;1381-1384.
13. Foss R.D., Guha-Thakurta N., Conran R.M., Gutman P. Effects of fixative and fixation time on the extraction and polymerase chain reaction amplification of RNA from paraffin-embedded tissue. Comparison of two housekeeping gene mRNA controls. Diagn. Mol. Pathol. 3:1994;148-155.
14. Hartung H.P., Archelos J.J., Zielasek J., Gold R., Koltzenburg M., Reiners K.H., Toyka K.V. Circulating adhesion molecules and inflammatory mediators in demyelination: a review. Neurology. 45:1995;S22-32.
15. Higgins P.J., Jone-Long K., Lobell R., Sardonini C., Alessi M.K., Yeh C.G. A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities. J. Immunol. 158:1997;2872-2881.
16. Hogan, B., Beddington, R., Constantini, F., Lacy, E., Manipulating the Mouse Embryo. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Plainview, NY, 1994.
17. Holers, V.M., 1995 Complement. In: Rich, R. (Ed.), Principles and Practices of Clinical Immunology. St. Louis, MO, Mosby, 1995, 363-391.
18. Johnson R.J., Alpers C.E., Pruchno C., Schulze M., Baker P.J., Pritzl P., Couser W.G. Mechanisms and kinetics for platelet and neutrophil localization in immune complex nephritis. Kidney Int. 36:1989;780-789.
19. Kalli K.R., Hsu P., Fearon D.T. Therapeutic uses of recombinant complement protein inhibitors. Springer Sem. Immunopathol. 15:1994;417-431.
20. Kim Y.-U., Kinoshita T., Molina H., Hourcade D., Seya T., Wagner L.M., Holers V.M. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J. Exp. Med. 181:1995;151-159.
21. Kinoshita T., Nussenzweig V. Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice: I. Isolation and characterization of factor H: the serum cofactor for the C3b/C4b inactivator (factor I). J. Immunol. Methods. 71:1984;247-257.
22. Li B., Sallee C., Dehoff M., Foley S., Molina H., Holers V.M. Mouse Crry/p65: Characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J. Immunol. 151:1993;4295-4305.
23. Mayadas T.N., Mendrick D.L., Brady H.R., Tang T., Papayianni A., Assmann K.J.M., Wagner D.D., Hynes R.O., Cotran R.S. Acute passive anti-glomerular basement nephritis in P-selectin-deficient mice. Kidney Int. 49:1996;1342-1349.
24. McCurry K.R., Kooyman D.L., Alvarado C.G., Cotterell A.H., Martin M.J., Logan J.S., Platt J.L. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat. Med. 1:1995;423-427.
25. Molina H., Wong W., Kinoshita T., Brenner C., Foley S., Holers V.M. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J. Exp. Med. 175:1992;121-129.
26. Moore F.D. Jr. Therapeutic regulation of the complement system in acute injury states. Adv. Immunol. 56:1994;267-299.
27. Morgan B.P. Physiology and pathophysiology of complement: progress and trends. Crit. Rev. Clin. Lab. Sci. 32:1995;265-298.
28. Morgan B.P., Gasque P., Singhrao S.K., Piddlesden S.J. Role of complement in inflammation and injury in the nervous system. Exp. Clin. Immunogenet. 14:1997;19-23.
29. Moulds J.M., Krych M., Holers V.M., Liszewski M.K., Atkinson J.P. Genetics of the complement system and rheumatic diseases. Rheum. Dis. Clin. North Am. 18:1992;893-914.
30. Nicholson-Weller A., Halperin J.A. Membrane signaling by complement C5b-9, the membrane attack complex. Immunol. Res. 12:1993;244-257.
31. Nilsson U.R., Müller-Eberhard H.J. Deficiency of the fifth component of complement in mice with an inherited complement defect. J. Exp. Med. 125:1967;1-16.
32. Ohly P., Gleichmann H. Metallothionein: in vitro induction with zinc and streptozotocin in pancreatic islets of mice. Exp. Clin. Endocrinol. Diabetes. 103:1995;79-82. Suppl 2.
33. Palmiter R.D., Norstedt G., Gelinas R.E., Hammer R.E., Brinster R.L. Metallothionein-human GH fusion genes stimulate growth of mice. Science. 222:1983;809-814.
34. Palmiter R.D., Sandgren E.P., Koeller D.M., Brinster R.L. Distal regulatory elements from the mouse metallothionein locus stimulate gene expression in transgenic mice. Mol. Cell Biol. 13:1993;5266-5275.
35. Piddlesden S.J., Storch M.K., Hibbs M., Freeman A.M., Lassmann H., Morgan B.P. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152:1994;5477-5484.
36. Quigg R.J. Glomerular injury induced by antibody and complement. Sem. Nephrol. 11:1991;259-267.
37. Quigg R.J., Abrahamson D.R., Cybulsky A.V., Badalamenti J., Minto A.W.M., Salant D.J. Studies with antibodies to cultured rat glomerular epithelial cells: subepithelial immune deposit formation after in vivo injection. Am. J. Pathol. 134:1989;1125-1133.
38. Quigg R.J., Lim A., Haas M., Alexander J.J., He C., Carroll M.C. Immune complex glomerulonephritis in C4- and C3-deficient mice. Kidney Int. 53:1998;320-330.
39. Quigg R.J., Kozono Y., Berthiaume D., Lim A., Salant D.J., Weinfeld A., Griffin P., Kremmer E., Holers V.M. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J. Immunol. 160:1998;4553-4560.
40. Quigg R.J., He C., Lim A., Berthiaume D., Alexander J.J., Kraus D., Holers V.M. Transgenic mice overexpressing the complement inhibitor Crry as a soluble protein are protected from antibody-induced glomerular injury. J. Exp. Med. 188:1998;1321-1331.
41. Salant D.J., Belok S., Madaio M.P., Couser W.G. A new role for complement in experimental membranous nephropathy in rats. J. Clin. Invest. 66:1980;1339-1350.
42. Schrijver G., Assmann K.J., Bogman M.J., Robben J.C., de Waal R.M., Koene R.A. Antiglomerular basement membrane nephritis in the mouse. Study on the role of complement in the heterologous phase. Lab. Invest. 59:1988;484-491.
43. Sheerin N.S., Springall T., Carroll M.C., Hartley B., Sacks S.H. Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin. Exp. Immunol. 110:1997;403-409.
44. Unanue E., Dixon F.J. Experimental glomerulonephritis. IV. Participation of complement in nephrotoxic nephritis. J. Exp. Med. 119:1964;965-982.
45. 1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. U.S.A. 93:1996;8563-8568.
46. Wang Y., Rollins S.A., Madri J.A., Matis L.A. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proc. Natl. Acad. Sci. U.S.A. 92:1995;8955-8959.
47. Weisman H.F., Bartow T., Leppo M.K., Marsh H.C. Jr., Carson G.R., Concino M.F., Boyle M.P., Roux K.H., Weisfeldt M.L., Fearon D.T. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science. 249:1990;146-151.
48. Wessels M.R., Butko P., Ma M., Warren H.B., Lage A.L., Carroll M.C. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. U.S.A. 92:1995;11490-11494.
49. Yamamoto T., Wilson C.B. Complement dependence of antibody-induced mesangial cell injury in the rat. J. Immunol. 138:1987;3758-3765.